Received Aug 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | X027447 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | UNK | Z005455 | — |
No additional AE; HCP reports that the patient received a dose of VARIVAX on 07/21/2025 and then a dose of MMR II on 07/28/2025. No symptomatic events were reported. No additional information provided. No additional AE/ no PQC. DILEUNT used to reconstitute the vacci; This spontaneous report was received from a Nurse and refers to a(n) patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 21-Jul-2025, the patient was vaccinated with a dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) injection, 0.5ml/ series, lot #Z005455 (reported as z005455), expiration date: 04-Mar-2027, administered for prophylaxis (route and strength was not reported). The Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot #Y020249 (reported as y020249), expiration date: 19-Oct-2027). On 28-Jul-2025, the patient was vaccinated with a dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) injection, 0.5ml/ series, lot #X027447 (reported as x027447), expiration date: 27-Nov-2025, administered for prophylaxis (route and strength was not reported). The Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) was reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot #2050911, expiration date: 11-Feb-2027) (Inappropriate schedule of product administration). No symptomatic events were reported. No additional information provided. No additional adverse event (AE) (No adverse event).
Sterile diluent